S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response

PTC Therapeutics (PTCT) Stock Price, News & Analysis

$26.42
-0.98 (-3.58%)
(As of 04/12/2024 ET)
Today's Range
$26.11
$28.01
50-Day Range
$24.15
$31.95
52-Week Range
$17.53
$59.84
Volume
736,837 shs
Average Volume
669,510 shs
Market Capitalization
$2.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.53

PTC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.85 Rating Score
Upside/​Downside
26.9% Upside
$33.53 Price Target
Short Interest
Bearish
13.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.41mentions of PTC Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$335,865 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.95) to ($5.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

299th out of 926 stocks

Pharmaceutical Preparations Industry

131st out of 419 stocks

PTCT stock logo

About PTC Therapeutics Stock (NASDAQ:PTCT)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Stock Price History

PTCT Stock News Headlines

These stocks are "on sale"
No matter what happens in the market; finding good companies to invest in when their stock prices are low is one of the best ways to build wealth using the stock market. These stocks could grow 10X their current price, which are currently a BARGAIN. Buying stocks like these when the market is down could lead to massive wealth and net worth growth when the markets go back up.
These stocks are "on sale"
No matter what happens in the market; finding good companies to invest in when their stock prices are low is one of the best ways to build wealth using the stock market. These stocks could grow 10X their current price, which are currently a BARGAIN. Buying stocks like these when the market is down could lead to massive wealth and net worth growth when the markets go back up.
PTC Therapeutics Gains After Announcement Of Key Regulatory Updates
PTC Therapeutics Submits BLA To FDA For Upstaza - Quick Facts
PTC Therapeutics Provides Key Regulatory Updates
PTC Therapeutics Q4 2023 Earnings Preview
PTC Therapeutics Inc (PTCT)
PTCT Jun 2024 10.000 put
PTCT Mar 2024 19.000 put
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/13/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTCT
Employees
988
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.53
High Stock Price Target
$55.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+26.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.85
Research Coverage
13 Analysts

Profitability

Net Income
$-626,600,000.00
Pretax Margin
-74.23%

Debt

Sales & Book Value

Annual Sales
$937.82 million
Cash Flow
$2.34 per share
Book Value
($10.85) per share

Miscellaneous

Free Float
72,548,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
0.67
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


PTCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" PTCT shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price target for 2024?

13 analysts have issued twelve-month price objectives for PTC Therapeutics' shares. Their PTCT share price targets range from $17.00 to $55.00. On average, they anticipate the company's stock price to reach $33.53 in the next year. This suggests a possible upside of 26.9% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2024?

PTC Therapeutics' stock was trading at $27.56 on January 1st, 2024. Since then, PTCT stock has decreased by 4.1% and is now trading at $26.42.
View the best growth stocks for 2024 here
.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our PTCT earnings forecast
.

How can I listen to PTC Therapeutics' earnings call?

PTC Therapeutics will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by $0.53. The biopharmaceutical company had revenue of $307.06 million for the quarter, compared to analyst estimates of $315.90 million.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $612.3 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTCT) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners